Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTRACT: Neoadjuvant Chemoimmunotherapy for TNBC
NCT05645380Phase 2Active, not recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in triple-negative breast cancer (TNBC) (3 arms), sponsored by University of Kansas Medical Center. Primary endpoint: Pathological Complete Response Rate at 26 weeks. Started Dec 2022; status: active, not recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05645380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05645380.